

Table 23.15
Cancer of the Prostate (Invasive)

Estimated United States Cancer Prevalence Counts^a on January 1, 2014
By Race/Ethnicity and Years Since Diagnosis

WARNING: The Prevalence Estimates presented on this page utilize a different tumor selection criteria from previous CSR releases and are NOT directly comparable to estimates from previous CSR releases. Please see the Prevalence Comparison Chapter of this CSR for more information.

Years Since Diagnosis	0 to <5	5 to <10	10 to <15	15 to <20	20 to <25	25 to <30	0 to <22 ^e	0 to <39 ^e	>=39 ^g	Complete ^h
<u>Race</u>										
All Races ^b	1,038,106	913,894	640,540	333,354	133,996	19,597	3,050,359	3,084,477	732	3,085,209
White ^b	831,557	751,537	541,036	285,443	119,819	17,768	2,520,665	2,551,678	878	2,552,556
Black ^b	153,415	121,969	79,312	39,027	11,428	1,481	404,551	407,038	73	407,111
Asian/Pacific Islander ^c	22,429	18,438	11,325	4,631	+	+	57,828	+	+	+
Hispanic ^d	62,617	50,575	31,586	14,998	+	+	162,771	+	+	+

Estimated prevalence percent^a on January 1, 2014, of the SEER^c population diagnosed in the previous 22 years
By Age at Prevalence and Race/Ethnicity

Age at Prevalence	Age Specific (Crude)										Age-Adjusted ^f
	All Ages	0-9	10-19	20-29	30-39	40-49	50-59	60-69	70-79	80+	All Ages
<u>Race</u>											
All Races ^c	1.6608%	-	0.0002%	0.0002%	0.0013%	0.0737%	1.0145%	4.9924%	12.5789%	16.4951%	1.7932%
White ^c	1.7681%	-	-	-	0.0011%	0.0644%	0.9596%	4.9247%	12.7390%	16.6536%	1.7953%
Black ^c	1.8660%	-	-	-	0.0034%	0.1951%	2.0595%	8.6530%	18.8869%	22.3298%	2.7793%
Asian/Pacific Islander ^c	0.7730%	-	-	-	-	0.0175%	0.3356%	2.0766%	6.1007%	10.1308%	0.8945%
Hispanic ^d	0.6046%	-	-	-	-	0.0398%	0.6047%	3.3682%	9.6657%	13.6355%	1.3650%

- ^a US 2014 cancer prevalence counts are based on 2014 cancer prevalence proportions from the SEER registries and 1/1/2014 US population estimates based on the average of 2013 and 2014 population estimates from the US Bureau of the Census.
- ^{b c d} Prevalence was calculated using the first invasive tumor for each cancer site diagnosed during the previous 39/22 years. Statistics based on (b) SEER 9 Areas (c) SEER 13 Areas excluding the Alaska Native Registry
- ^e (d) NHIA for Hispanic for SEER 13 Areas excluding the Alaska Native Registry.
- ^f Maximum limited-duration prevalence: 39 years for 1975-2014 SEER 9 data; 22 years for 1992-2014 SEER 13 data (excluding the Alaska Native Registry) used to calculate prevalence for Hispanics and Asian Pacific Islanders.
- ^{g h i} Percentages are age-adjusted to the 2000 US Standard Population (19 age groups - Census P25-1130) by 5-year age groups. (g) Cases diagnosed more than 39 years ago were estimated using the completeness index method (Capocaccia et. al. 1997, Merrill et. al. 2000). (h) Complete prevalence is obtained by summing 0 to <39 and >=39. (i) Age-specific completeness index was approximated using empirical data from historical Connecticut tumor registry.
- Statistic not shown. Statistic based on fewer than 5 cases estimated alive in SEER for the time interval.
- + Not available.